含胸腺肽免疫增强的自体CIK细胞联合IL-2方案治疗高龄弥漫大B细胞淋巴瘤

杨洋; 杨波; 脱帅; 卢学春; 朱宏丽; 脱朝伟; 蔡力力; 迟小华; 于睿莉; 陈云燕; 张文英; 刘洋; 王瑶; 代汉仁; 韩为东; 张峰; 姚善谦

含胸腺肽免疫增强的自体CIK细胞联合IL-2方案治疗高龄弥漫大B细胞淋巴瘤

1 解放军总医院南楼血液科, 北京 100853;
2 解放军第 202 医院, 沈阳 110003;
3 解放军第二炮兵总医院药学部, 北京 100800;
4 解放军第二炮兵后勤部保健办, 北京 100800;
5 中国科学院北京基因组研究所, 北京 100029

基金项目:

国家自然科学基金项目 (30772597), 解放军总医院科技创新苗圃基金 (11KMM24), 中央保健研究基金 (B2009B115), 科技部新药创制重大专项 (2008ZXJ09001-019)

详细信息

作者简介:
杨洋,女,硕士,医师。研究方向:老年血液肿瘤。Email:yangyangbj1022@163.com

通讯作者:
卢学春,男,博士,主任医师。Email:luxuechun@126.com

朱宏丽,女,博士,主任医师,主任。Email:bjzhl202_cn@sina.com

中图分类号: R 733.41
计量
- 文章访问数: 28
- HTML全文浏览量: 7
- PDF下载量: 26
出版历程
- 收稿日期: 2011-09-06
- 修回日期: 2011-10-17
- 网络出版日期: 2023-11-27
- 刊出日期: 2012-05-27

Treatment of diffuse large B cell lymphoma with combined thymic peptide-enhanced autologous cytokine induced killer cells and IL-2 in aged patients

1 Department of Geriatric Hemo, Chinese PLA General Hospital, Beijing 100853, China;
2 Chinese PLA 202 Hospital, Shenyang 110003, Liaoning province, China;
3 Department of Pharmacy, General Hospital of Chinese PLA Second Artillery Forces, Beijing 100800, China;
4 Health Care Office, Logistics Department, Chinese PLA Second Artillery Forces, Beijing 100800, China;
5 Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100029, China

Funds:

Supported by the National Natural Science Foundation of China (30772597)

摘要

摘要: 目的评价含胸腺肽免疫增强的自体CIK细胞联合IL-2 (TCIL-2) 方案治疗高龄弥漫大B细胞淋巴瘤的有效性和安全性。方法采集预先接受胸腺五肽免疫增强治疗的4例高龄弥漫大B细胞淋巴瘤 (DLBCL) 患者外周血单个核细胞, 在体外经干扰素-γ (IFN-γ) 、白介素-2 (IL-2) 、抗CD3单克隆抗体诱导成CIK细胞, 回输细胞数为2×10⁹-3×10⁹个, 回输后应用IL-2 100mU/d, 皮下注射, 连续10d。28d为1个周期, 共完成24个周期的自体CIK细胞输注。观察治疗前后细胞免疫功能、肿瘤相关生物学指标变化。结果 2例接受8个周期的CIK细胞输注, 2例接受4个周期的输注, 回输后所有患者未出现不良反应。CIK细胞治疗后CD3⁺、CD3⁺CD8⁺、CD3sup>+CD56⁺细胞比例明显升高 (P＜0.05), β2微球蛋白水平显著下降 (P＜0.05) 。3例达完全缓解, 1例完成8周期的CIK细胞输注后一度达良好的部分缓解, 但最终因急性心肌梗死和淋巴瘤持续进展而死亡。结论自体CIK细胞联合IL-2治疗高龄弥漫大B细胞淋巴瘤安全有效。
- 细胞因子诱导的杀伤细胞 /
- 胸腺肽 /
- 淋巴瘤 /
- 弥漫大B细胞 /
- 老年人
Abstract: Objective To assess the efficiency and safety of combined thymic peptide-enhanced autologous cytokine induced killer（CIK） cells and IL-2 in treatment of diffuse large B cell lymphoma in aged patients. Methods Peripheral blood mononuclear cells（PBMC） were collected from 4 aged patients with diffuse large B cell lymphoma.CIK cells were induced with in vitro interferon gamma（IFN-γ）,IL-2 and anti-CD3 monoclonal antibody（mAb）.Immune function of the cells and tumor-related biological indexes of the patients were observed after 2×10⁹-3×10⁹ autologous CIK cells were re-transfused into the patients each time and IL-2 100mU/d was subcutaneously injected for 10 days,28 days a cycle for 24 cycles. Results Two patients received 8 cycles of CIK cells transfusion and 2 patients received 4 cycles of CIK cells transfusion.No adverse reaction occurred in them.The number of CD3⁺,CD3⁺CD8⁺ and CD3³⁺CD56⁺ was significantly greater and the serum β2-microglobulin level was markedly lower after CIK cells transfusion than before CIK cells transfusion（P＜0.05）.Complete remission was achieved in 3 patients and 1 patient died of acute large-area myocardial infarction and persistent progression of lymphoma although partial remission was achieved after 8 cycles of CIK cells transfusion. Conclusion Combined autologous CIK cells transfusion and IL-2 is safe and effective for large B cell lymphoma in aged patients.
- cytokine induced killer cells /
- thymosin /
- lymphoma /
- diffuse large b cell lymphoma /
- aged